Acadia Pharmaceuticals (ACAD) news
Recent news
Acadia Pharmaceuticals Inc.: Deutsche Bank raises target price to $38 from $37
AInvest Wire · 6d agoAcadia Pharmaceuticals Inc.: UBS raises target price to $49 from $45
AInvest Wire · Aug 17, 2026Oppenheimer raises target price to $25 from $23 for Acadia Pharmaceuticals, Inc.
AInvest Wire · Aug 5, 2026Neuren: now sees CY26 royalty income of $53M - $56M
Neuren Pharmaceuticals Ltd (ASX: NEU) has revised its 2026 royalty income projections for DAYBUE (trofinetide) to a range of A$53 million to A$56 million, reflecting updated expectations for the drug’s global performance. This adjustment follows Acadia Pharmaceuticals’ Q1 2026 sales of US$101…
AInvest Wire · Aug 4, 2026Acadia Pharmaceuticals: Lowers FY2026 R&D expense guidance to $355-$380 mln
Acadia Pharmaceuticals has revised its full-year 2026 research and development (R&D) expense guidance, narrowing the range to $355–$380 million, down from the previously stated $385–$410 million . This adjustment reflects a strategic reallocation of resources to optimize efficiency in its clinical…
AInvest Wire · Aug 4, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.